Maudelonde T - Search Results

1

Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.

Rouanet P, Linares-Cruz G, Dravet F, Poujol S, Gourgou S, Simony-Lafontaine J, Grenier J, Kramar A, Girault J, Le Nestour E, Maudelonde T. Rouanet P, et al. Among authors: maudelonde t. J Clin Oncol. 2005 May 1;23(13):2980-7. doi: 10.1200/JCO.2005.06.064. J Clin Oncol. 2005. PMID: 15860853 Clinical Trial.

2

Neoadjuvant tamoxifen for operable breast cancer: a need for phase III studies?

Pujol P, Daures JP, Rouanet P, Hermand J, Domergue J, Grenier J, Maudelonde T. Pujol P, et al. Among authors: maudelonde t. Cancer Detect Prev. 2000;24(5):445-51. Cancer Detect Prev. 2000. PMID: 11129986 Clinical Trial.

3

Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J. Desmetz C, et al. Among authors: maudelonde t. Clin Cancer Res. 2009 Jul 15;15(14):4733-41. doi: 10.1158/1078-0432.CCR-08-3307. Epub 2009 Jul 7. Clin Cancer Res. 2009. PMID: 19584157

4

A prospective prognostic study of the hormonal milieu at the time of surgery in premenopausal breast carcinoma.

Pujol P, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T. Pujol P, et al. Among authors: maudelonde t. Cancer. 2001 May 15;91(10):1854-61. Cancer. 2001. PMID: 11346866

5

In vivo stimulation by tamoxifen of cathepsin D RNA level in breast cancer.

Maudelonde T, Escot C, Pujol P, Rouanet P, Defrenne A, Brouillet JP, Rochefort H. Maudelonde T, et al. Eur J Cancer. 1994;30A(14):2049-53. doi: 10.1016/0959-8049(94)00343-4. Eur J Cancer. 1994. PMID: 7857701

6

Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer.

Mangé A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy PJ, Rouanet P, Maudelonde T, Solassol J. Mangé A, et al. Among authors: maudelonde t. Clin Cancer Res. 2012 Apr 1;18(7):1992-2000. doi: 10.1158/1078-0432.CCR-11-2527. Epub 2012 Feb 9. Clin Cancer Res. 2012. PMID: 22322670

7

Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.

Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H. Le Roy X, et al. Among authors: maudelonde t. Oncogene. 1991 Mar;6(3):431-7. Oncogene. 1991. PMID: 1707153

8

Correlation between mannose-6-phosphate/IGFII receptor and cathepsin D RNA levels by in situ hybridization in benign and malignant mammary tumors.

Zhao Y, Escot C, Maudelonde T, Puech C, Rouanet P, Rochefort H. Zhao Y, et al. Among authors: maudelonde t. Cancer Res. 1993 Jun 15;53(12):2901-5. Cancer Res. 1993. PMID: 7684951

9

A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol.

Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H. Pujol P, et al. Among authors: maudelonde t. Cancer. 1993 Mar 15;71(6):2006-12. doi: 10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q. Cancer. 1993. PMID: 8443752

10

Analysis of the potential contribution of estrogen receptor (ER) beta in ER cytosolic assay of breast cancer.

Brouillet JP, Dujardin MA, Chalbos D, Rey JM, Grenier J, Lamy PJ, Maudelonde T, Pujol P. Brouillet JP, et al. Among authors: maudelonde t. Int J Cancer. 2001 Jul 20;95(4):205-8. doi: 10.1002/1097-0215(20010720)95:4<205::aid-ijc1035>3.0.co;2-y. Int J Cancer. 2001. PMID: 11400111

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters